Therapeutic target mapping using explanted heart samples
A therapeutic target mapping workflow using diseased explanted heart tissue to improve drug candidate response prediction. By generating high-quality diseased 'Omics' datasets, the approach supports de novo target design and compound screening for known pharmacology while addressing challenges from cellular heterogeneity and model differences.
Overview
The proposed solution leverages high-quality explanted heart samples to map therapeutic targets, enhancing the prediction of drug candidate responses. This approach addresses the challenge of accurately predicting human drug effects due to cellular heterogeneity and model differences. By generating diseased 'Omics' datasets, the process facilitates both de novo target design and compound screening for known pharmacology.
Technical specifications
- Utilizes high-throughput methods such as RNA sequencing and proteomics to identify potential therapeutic targets.
- Offers expertise in RNA sequencing, including bulk and single nuclei RNA-seq.
- Incorporates spatial gene expression and multiplex imaging for comprehensive analysis.
- Employs bioinformatic analysis to interpret complex datasets and identify promising therapeutic targets.
Technology readiness level
The technology is at TRL 5, having been validated in relevant environments with ongoing development for further validation.
About University of British Columbia
UBC is a comprehensive public research university with major campuses in Vancouver and the Okanagan, among Canada’s largest and most internationally connected. Industry engages through a co-op talent pipeline and collaborative research spaces that include co-located clinical settings and on‑campus testbeds. A dedicated technology transfer office brokers partnerships, manages IP and licensing, and is complemented by an active venture accelerator and incubator network. Research is supported by competitive funding from Canada’s Tri‑Council agencies (NSERC, CIHR, SSHRC) and infrastructure investments from the Canada Foundation for Innovation, alongside provincial and industry sponsorship.
delivered to your inbox.